The GNS Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-HEP-1 human hepatic adenocarcinoma cell line, with targeted disruption of the GNS gene. This product supplies a heterogeneous pool of edited cells, enabling population-level analysis of gene function.
The SK-HEP-1 line, originally isolated from ascitic fluid of a liver adenocarcinoma patient, displays an epithelial phenotype with endothelial characteristics, making it a valuable model for liver cancer metastasis and tumor?Cstroma interactions. Its dual identity facilitates studies on the transition between epithelial and endothelial states in oncology.
GNS encodes a lysosomal sulfatase that hydrolyzes 6-sulfate groups from N-acetyl-D-glucosamine residues within heparan sulfate and keratan sulfate, essential for normal glycosaminoglycan degradation. The enzyme’s activity is post-translationally modified and activated by SUMF1 (sulfatase-modifying factor 1), and its expression is under the transcriptional control of TFEB, a master regulator of lysosomal biogenesis and autophagy. Disruption of GNS abolishes sulfatase activity, resulting in the intralysosomal buildup of heparan sulfate oligosaccharides, including N-acetylglucosamine-6-sulfate. This accumulation mirrors the biochemical hallmark of mucopolysaccharidosis type IIID (Sanfilippo D syndrome), leading to lysosomal dysfunction, impaired autophagy, and altered cellular homeostasis.
Within the SK-HEP-1 hepatocellular carcinoma background, this knockout creates a tractable in vitro system for investigating the consequences of lysosomal storage in liver-derived cells. The model is particularly suited to study how defects in glycosaminoglycan catabolism intersect with cancer-relevant processes such as cell adhesion, motility, and metabolic adaptation. Moreover, the endothelial-like properties of the host line provide a unique dimension for examining vascular contributions to lysosomal storage disorders.
This polyclonal knockout model supports diverse experimental applications, including mechanistic studies of GNS-mediated glycosaminoglycan metabolism, disease modeling of mucopolysaccharidosis type IIID, and high-throughput drug screening for candidate therapeutics that reduce lysosomal storage. Commonly employed assays include western blotting for GNS protein, sulfatase activity assays using fluorogenic substrates, immunofluorescence staining for heparan sulfate accumulation, lysosomal pH measurements, LC-MS/MS profiling of glycosaminoglycans, and RT-qPCR quantification of GNS mRNA. For additional information, please contact Ascent Research.
